Bal Pharma share price today is Rs 98.98, up Rs 4.7 or 5%. The stock is at 5% upper circuit. The market cap of the company is just below Rs 150 cr. This is a small cap pharma company. The 52 week low of the stock is Rs 34 and 52 week high is Rs 137.7. 

COMMERCIAL BREAK
SCROLL TO CONTINUE READING

Bal Pharma in its BSE release yesterday announced the launch of Favipiravir formulation into Indian market, under the brand name BALflu. Favipiravir is an emerging anti viral drug used for patients with mild to moderate Covid-19 infection. This formulation is available in tablet form with 400 mg strength. Favipiravir inhibits and terminates viral protein synthesis and induces lethal metagenesis of influenza virus. 

BALflu (Favipiravir) is a broad spectrum formulation also used in the treatment of 53 types of Influenza virus including seasonal strains such as Ebola virus, arenavirus, bunyavirus, flovirus, west nile virus , food & mouth disease virus and lassa virus. 

See Zee Business Live TV Streaming Below:

BALflu (Favipiravir) is approved by Drug Controller General of India (DCGI) for emergency use for the treatment of COVID-19 with an recommended dosage of 1800 mg on the first day followed by 800 mg from day 2 to 14. 

Shailesh Siroya , Managing Director of Bal Pharma at the launch of the product has said that the BALflu has the efficacy to clear the virus faster by 28.7% and is marketed at a very affordable price of Rs.85 per tablet, so as to enable the needy patients to access this drug on time. BALflu (Favipiravir) is made available across all the major markets in India as a prescription drug.